# Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

> **NCT00309608** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 333 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Linagliptin
- **DRUG:** Linagliptin
- **DRUG:** Placebo
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT00309608
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309608, "Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00309608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*